Alzheimer’s disease is a type of dementia and also the most common cause of dementia. Dementia refers to a number of symptoms that include loss of memory (especially short-term memory) as well as problems with the use of language. Further symptoms include difficulties with thinking, problem-solving or language.
The disease is caused by a build-up of proteins in the brain. ‘Plaques’ and nerve ‘tangles’ are formed and these impact on the connections between nerve cells in the brain, eventually causing the death of some of these cells.
Brain function is also dependent on chemical transmitters and some these also become depleted in Alzheimer’s Disease.
Alzheimer’s Disease typically has a gradual progression and it is often difficult to determine exactly when the illness started.
A further characteristic of Alzheimer’s Disease is that it is a disease of the elderly. It is relatively rare below the age of 60, and becomes progressively more common as age increases.
Want to be part of our Clinical Trials?
The Cognitiv|AD clinical trial is evaluating the safety and effectiveness of a study medication used in mild to moderate Alzheimer’s disease patients currently or previously taking:
- Aricept (Donepezil Hydrochloride)
- Reminyl (galantamine)
- Exelon (rivastigmine)
Patients eligible for the Cognitive|AD Clinical trial could create hope for the future!
Contact us – Helderberg Memory Centre -Somerset-West – and find out how you can be part of our clinical trials.